Takeda Exercises Option to Acquire PvP Biologics
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 3 (Table of Contents)
Published: 7 Mar-2020
DOI: 10.3833/pdr.v2020.i3.2519 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Triggered by a Phase I data read out for TAK-062, Takeda Pharmaceutical has exercised an option given to it as part of a 2017 agreement to acquire PvP Biologics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS